CELLSEARCH® Circulating Tumor Cell Test in metastatic prostate cancer (mPC)—clinical trials and real-world case studies
Pivotal Clinical Trial—circulating tumor cells (CTCs) predict disease progression and survival in patients with mPC*1,2
Two hundred thirty-one patients with histologically confirmed mPC who were starting a new line of therapy were monitored with CTCs and prostate-specific antigen (PSA) levels at baseline and monthly thereafter.1
- de Bono, JS, et al. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2008;14:6302-6309.
- CELLSEARCH® Circulating Tumor Cell Kit (Epithelial) Instructions for Use. Janssen Diagnostics, LLC.